← Maze Therapeutics, Inc. (MAZE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Maze Therapeutics, Inc. (MAZE)
Biological Products, (No Diagnostic Substances) · market cap $1.6B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Maze Therapeutics (MAZE) is a clinical-stage biotech with ~125 employees and a $1.56B market cap, advancing two Phase 2 assets: MZE829 in proteinuric kidney disease and MZE782 in phenylketonuria (PKU). The company carries $198.8M in cash against a burn rate implying roughly 15 months of runway, with no revenue and $131M in net losses in 2025. A Phase 2 readout for MZE829 is estimated around September 15, 2026, representing the near-term binary event.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MZE829 | Phase 2 | Proteinuric Kidney Disease |
| MZE782 | Phase 2 | Phenylketonuria (PKU) |
Price & technical context
3-month
-17.5%
6-month
-7.0%
12-month
+3.4%
52-wk range
$22.39–$51.83
vs 50-day MA
-1.1%
vs 200-day MA
-19.1%
Realized vol
70.2%
Max drawdown
-56.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MAZE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.